Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01236547 · ClinicalTrials.gov registry record · Phase 2
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT01236547: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01236547 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 123 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01236547, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and paclitaxel are more effective when given with pazopanib hydrochloride in treating thyroid cancer.
Interventions
- DRUG Paclitaxel
- RADIATION Intensity-Modulated Radiation Therapy
- OTHER Placebo Administration
- DRUG Pazopanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2010-10-28 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01236547
The ClinicalTrials.gov registry entry for NCT01236547 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT01236547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01236547 about?
NCT01236547 is a clinical study titled "Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer". This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer. Specialized radiation therapy that delivers a high dose of radiation dir...
What is the current status of trial NCT01236547?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2010-10-28. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT01236547?
The interventions under investigation include: Paclitaxel (DRUG), Intensity-Modulated Radiation Therapy (RADIATION), Placebo Administration (OTHER), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01236547?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.